Vivek Subbiah: Kicking off the new year 2024 with a bang!

Vivek Subbiah shared on X:

“Kicking off the new year 2024 with a bang! 

Thrilled to announce our precision medicine publication in one of the HIGHEST impact factor journals in Oncology.

Interpreting and integrating genomic test results in clinical cancer care.

Gratitude to the incredible team behind it! Check it out now! 

Spearheaded by the terrific Raffaella Casolino and many other amazing colleagues.

Additional details.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.